CA2512249A1 - Compositions of polymerized wheat proteins and ethanolamine derivatives - Google Patents
Compositions of polymerized wheat proteins and ethanolamine derivatives Download PDFInfo
- Publication number
- CA2512249A1 CA2512249A1 CA002512249A CA2512249A CA2512249A1 CA 2512249 A1 CA2512249 A1 CA 2512249A1 CA 002512249 A CA002512249 A CA 002512249A CA 2512249 A CA2512249 A CA 2512249A CA 2512249 A1 CA2512249 A1 CA 2512249A1
- Authority
- CA
- Canada
- Prior art keywords
- polymerized
- composition
- skin
- ethanolamine
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 98
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 48
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 48
- 241000209140 Triticum Species 0.000 title claims abstract description 40
- 235000021307 Triticum Nutrition 0.000 title claims abstract description 40
- 150000002169 ethanolamines Chemical class 0.000 title claims abstract description 15
- 238000009472 formulation Methods 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 21
- 239000012049 topical pharmaceutical composition Substances 0.000 claims abstract description 15
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000004615 ingredient Substances 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 12
- -1 hydroxy, methoxy Chemical group 0.000 claims description 12
- 230000000699 topical effect Effects 0.000 claims description 12
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical group OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 11
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 10
- 229960002887 deanol Drugs 0.000 claims description 10
- 239000012071 phase Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 230000000379 polymerizing effect Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000032683 aging Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 2
- 238000006911 enzymatic reaction Methods 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 230000003381 solubilizing effect Effects 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 1
- 230000009759 skin aging Effects 0.000 abstract description 13
- 230000003712 anti-aging effect Effects 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 40
- 210000003491 skin Anatomy 0.000 description 27
- 239000002253 acid Substances 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- 150000007513 acids Chemical class 0.000 description 8
- 239000003974 emollient agent Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GLCFQKXOQDQJFZ-UHFFFAOYSA-N 2-ethylhexyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(CC)CCCC GLCFQKXOQDQJFZ-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000018389 Exopeptidases Human genes 0.000 description 2
- 108010091443 Exopeptidases Proteins 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000037393 skin firmness Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- WKAVKKUXZAWHDM-UHFFFAOYSA-N 2-acetamidopentanedioic acid;2-(dimethylamino)ethanol Chemical compound CN(C)CCO.CC(=O)NC(C(O)=O)CCC(O)=O WKAVKKUXZAWHDM-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- DHFUFHYLYSCIJY-WSGIOKLISA-N CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DHFUFHYLYSCIJY-WSGIOKLISA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VTJBUEPNESMAHX-UHFFFAOYSA-N Citricolic acid Natural products CC(C=CC(C)C1(O)CCC2C3=CC(=O)OC3(O)CCC12C)C(C)(C)O VTJBUEPNESMAHX-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000005905 Hydrolysed protein Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- CBKLICUQYUTWQL-XWGBWKJCSA-N methyl (3s,4r)-3-methyl-1-(2-phenylethyl)-4-(n-propanoylanilino)piperidine-4-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.CCC(=O)N([C@]1([C@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 CBKLICUQYUTWQL-XWGBWKJCSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940086539 peg-7 glyceryl cocoate Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001228 polyisocyanate Polymers 0.000 description 1
- 239000005056 polyisocyanate Substances 0.000 description 1
- 239000012985 polymerization agent Substances 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229940023565 ppg-10 cetyl ether Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- QYNMSPKSYXPZHG-UHFFFAOYSA-M sodium;4-ethoxycarbonylphenolate Chemical compound [Na+].CCOC(=O)C1=CC=C([O-])C=C1 QYNMSPKSYXPZHG-UHFFFAOYSA-M 0.000 description 1
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 1
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention relates to compositions comprising an ethanolamine derivative and a polymerized wheat protein. It further relates to the use of such compositions in topical formulations, in particular in anti-aging formulations. The invention further relates to the use of such compositions to combat the effects of skin aging.
Description
Compositions of Polymerized Wheat Proteins arid Ethanolamine Derivatives Brief description of the invention This invention relates to compositions comprising an ethanolamine derivative and a polymerized wheat protein. It further relates to the use of such compositions in topical formulations, in particular in anti-aging formulations. The invention further relates to the use of such compositions to combat the effects of skin aging.
Background of the Invention The appearance and condition of the skin may be degraded through external factors such as sunlight, exposure to wind and to cool and dry air, air pollutants, smoking, as well as internal factors such as dermatological diseases, age-related hormonal changes, or the normal aging process.
As a first sign of aging, skin becomes less elastic and develops fine lines and wrinkles, which are the direct result of deterioration of the supporting dermis layer.
In fact the skin's ability to replace damaged collagen diminishes and more and more disconnections and irregularities develop in the collagen network. Further phenomena associated with skin aging are the appearance of pigment marks, skin thinning and skin sagging.
Cosmetic products have been developed that have proved out to be more or less effective in combating the effects of skin aging. Particular such products are those containing vitamins or vitamin derivatives, in particular vitamin A or its derivatives (retinoids), vitamin C, alpha-hydroxy acids or plant extracts. These products, when applied regularly during longer periods of time, have been shown to reduce the number of wrinkles and fine wrinkles. A particular pathway used in the tareatrnent of the effects CONFIRMATION COPY
Background of the Invention The appearance and condition of the skin may be degraded through external factors such as sunlight, exposure to wind and to cool and dry air, air pollutants, smoking, as well as internal factors such as dermatological diseases, age-related hormonal changes, or the normal aging process.
As a first sign of aging, skin becomes less elastic and develops fine lines and wrinkles, which are the direct result of deterioration of the supporting dermis layer.
In fact the skin's ability to replace damaged collagen diminishes and more and more disconnections and irregularities develop in the collagen network. Further phenomena associated with skin aging are the appearance of pigment marks, skin thinning and skin sagging.
Cosmetic products have been developed that have proved out to be more or less effective in combating the effects of skin aging. Particular such products are those containing vitamins or vitamin derivatives, in particular vitamin A or its derivatives (retinoids), vitamin C, alpha-hydroxy acids or plant extracts. These products, when applied regularly during longer periods of time, have been shown to reduce the number of wrinkles and fine wrinkles. A particular pathway used in the tareatrnent of the effects CONFIRMATION COPY
of skin aging is by stimulation of dermal human fibroblasts and collagen formation.
Agents possessing these properties for example are L-ascorbic acid and in particular retinol.
Other agents that have been described as useful to treat the effects of skin aging are the ethanolamine derivatives. US 5,554,647 describes a method of treating aging skin and subcutaneous muscles comprising the use of an acetylcholine precursor such as dimethylaminoethanol (DMAE) in an amount effective to produce increased muscle tone.
US 5,643,586 describes the topical treatment of subcutaneous muscle and overlying cutaneous tissue by applying a composition comprising a catecholamine precursor which in particular is tyrosine, phenylalanine or a mixture thereof preferably in combination with an acetylcholine precursor such as dimethylaminoethanol.
EP-A-1219288 relates to a topical composition for the treatment of skin, in particular to improve skin firmness, comprising an effective amount of an ethanolamine salt which has a mixture of anionic counterions derived from at least two pharmaceutically acceptable acids and esters thereof; and a cosmetically acceptable carrier.
This reference teaches that the ethanolamines as disclosed therein affect the biomechanical properties of the skin thus restoring youthful firmness resulting in improved facial contours.
Although these methods and the products used therein have been applied with varying degrees of success, there nevertheless remains room for improvement. In particular there still is a need for new formulations that are more effective in combating the effects of the skin aging process.
The compositions and formulations according to the present invention, which will be described hereinafter. in more detail, are aimed at being effective tools in combating the effects of skin aging.
Agents possessing these properties for example are L-ascorbic acid and in particular retinol.
Other agents that have been described as useful to treat the effects of skin aging are the ethanolamine derivatives. US 5,554,647 describes a method of treating aging skin and subcutaneous muscles comprising the use of an acetylcholine precursor such as dimethylaminoethanol (DMAE) in an amount effective to produce increased muscle tone.
US 5,643,586 describes the topical treatment of subcutaneous muscle and overlying cutaneous tissue by applying a composition comprising a catecholamine precursor which in particular is tyrosine, phenylalanine or a mixture thereof preferably in combination with an acetylcholine precursor such as dimethylaminoethanol.
EP-A-1219288 relates to a topical composition for the treatment of skin, in particular to improve skin firmness, comprising an effective amount of an ethanolamine salt which has a mixture of anionic counterions derived from at least two pharmaceutically acceptable acids and esters thereof; and a cosmetically acceptable carrier.
This reference teaches that the ethanolamines as disclosed therein affect the biomechanical properties of the skin thus restoring youthful firmness resulting in improved facial contours.
Although these methods and the products used therein have been applied with varying degrees of success, there nevertheless remains room for improvement. In particular there still is a need for new formulations that are more effective in combating the effects of the skin aging process.
The compositions and formulations according to the present invention, which will be described hereinafter. in more detail, are aimed at being effective tools in combating the effects of skin aging.
Summary of the invention In a first aspect, the present invention is directed to a composition comprising at least one ethanolamine derivative of formula (I), or a skin acceptable salt thereof:
Ri N-CHZ-CH2-OH (I), and at least one polymerized wheat protein.
In formula (I) Rl and RZ independently represent hydrogen, C3_6 cycloalkyl or Cl_~
alkyl, optionally substituted with hydroxy, methoxy, oxo or formyl.
Preferably R1 and R2 independently represent C1_4 alkyl.
The most preferred ethanolamine of formula (I) is dimethylaminoethanol (1~MAE), also referred to as deanol.
The polymerized wheat protein is obtainable from hydrolyzed wheat protein hydrolysates, which are polymerized by using an appropriate multifunctional polymerizing agent.
The invention further is concerned with a topical formulation comprising a composition as defined herein and a cosmetically-acceptable or dermatologically-acceptable topical carrier. The latter may comprise one or more further ingredients. The topical formulation can be for dermatological use but is in particular for cosmetic use.
In another aspect the invention provides the use of a composition as defined herein for manufacturing a topical or in particular a cosmetic formulation. The topical or cosmetic formulations are useful for combating or treating the effects of skin aging.
Ri N-CHZ-CH2-OH (I), and at least one polymerized wheat protein.
In formula (I) Rl and RZ independently represent hydrogen, C3_6 cycloalkyl or Cl_~
alkyl, optionally substituted with hydroxy, methoxy, oxo or formyl.
Preferably R1 and R2 independently represent C1_4 alkyl.
The most preferred ethanolamine of formula (I) is dimethylaminoethanol (1~MAE), also referred to as deanol.
The polymerized wheat protein is obtainable from hydrolyzed wheat protein hydrolysates, which are polymerized by using an appropriate multifunctional polymerizing agent.
The invention further is concerned with a topical formulation comprising a composition as defined herein and a cosmetically-acceptable or dermatologically-acceptable topical carrier. The latter may comprise one or more further ingredients. The topical formulation can be for dermatological use but is in particular for cosmetic use.
In another aspect the invention provides the use of a composition as defined herein for manufacturing a topical or in particular a cosmetic formulation. The topical or cosmetic formulations are useful for combating or treating the effects of skin aging.
In a further aspect, the invention provides the use, and more specifically the cosmetic use, of a composition as defined herein, or of a topical formulation as defined herein, for combating or treating the effects associated with the aging of skin.
Or, alternatively, the invention concerns a method, and in particular a cosmetic method, of combating or treating the effects of skin aging, which method or cosmetic method comprises applying to the affected skin area an amount of a composition or of a topical formulation as defined herein, said amount being effective to treat said effects of skin aging.
Still another aspect of this invention comprises a cosmetic method for the improvement of the external appearance of an individual, said method comprising applying an effective amount of a composition or a topical composition as defined herein to affected skin areas.
Detailed description of the invention As used herein, any percentage is weight-by-weight (w/w) relative to the total weight of the composition or of the formulation.
As further used herein, 'effective amount' means an amount of composition or formulation sufficient to significantly induce a positive modification in the condition to be regulated or treated, but low enough to avoid serious side effects. The effective amount of the composition or formulation will vary with the particular condition being treated, the age and physical condition of the end user, the severity of the condition being treated/prevented, the duration of the treatment, the nature of concurrent therapy, the specific composition or formulation employed, the particular cosmetically-acceptable topical carrier utilized, and like factors.
The compositions of this invention comprise polymerized wheat proteins of high molecular weight. These polymerized wheat proteins can be prepared by a process comprising the following steps 1) solubilizing in an aqueous phase a material which is rich in wheat proteins;
2) hydrolyzing by enzymatic reaction in a controlled and limited manner the solution of 1) wherein the level of enzymatic hydrolysis is selected such that monomeric proteins with a molar mass between 20,000 Da and 300,000 Da are obtained;
3) separating the soluble phases from the insoluble phases;
4) polymerizing the proteins by adding a suitable polymerizing agent.
The source of wheat proteins used in the first step can be any material derived from wheat that is sufficiently rich in wheat proteins. Suitable materials are, for example, wheat flour, wheat extracts, wheat gluten and the like.
The process preferably is conducted under following circumstances. The starting wheat protein rich material is solubilized at a concentration of 50 g/1 to 500 g/1.
Subsequently, the hydrolysis is carned out preferably in acid pH, preferably at a pH
level in the range between 4 and 7 and at a temperature between 40°C
and 80°C.
The enzymes that can be used in the hydrolysis step are proteases of the following type:
endoproteases, exoproteases, exopeptidases, proteasepeptidases, aminomeptidases or carbopeptidases, or a mixture of these enzymes. After completion of the reaction the enzymes are inactivated, for example by increasing the temperature of the reaction mixture to a temperature between 50°C and 80°C. The level of hydrolysis is selected such that the percentage of hydrolysed wheat protein in fractions F2 and F3 is between about 70 : 60 to about 50 : 40 and in particular is about 50 : 50 (+l- 5%), with no or almost no hydrolysed protein in fraction F1 (preferably less than about 5%), wherein Fl, F2 and F3 are as defined hereinafter.
The polymerizing agent preferably is a multifunctional polymerizing agent selected from the group of polymerization initiators comprising polychlorides of acids, acid polyanhydrides, polyisocyanates, polythioisocyanates. The polymerization step is preferably carried out with a level of polymerization agent between 10 g/1 and 100 g/1, selected so as to obtain a level of polymerized proteins that is higher than 30%.
Preferably about one equivalent of the polymerizing agent is used.
Or, alternatively, the invention concerns a method, and in particular a cosmetic method, of combating or treating the effects of skin aging, which method or cosmetic method comprises applying to the affected skin area an amount of a composition or of a topical formulation as defined herein, said amount being effective to treat said effects of skin aging.
Still another aspect of this invention comprises a cosmetic method for the improvement of the external appearance of an individual, said method comprising applying an effective amount of a composition or a topical composition as defined herein to affected skin areas.
Detailed description of the invention As used herein, any percentage is weight-by-weight (w/w) relative to the total weight of the composition or of the formulation.
As further used herein, 'effective amount' means an amount of composition or formulation sufficient to significantly induce a positive modification in the condition to be regulated or treated, but low enough to avoid serious side effects. The effective amount of the composition or formulation will vary with the particular condition being treated, the age and physical condition of the end user, the severity of the condition being treated/prevented, the duration of the treatment, the nature of concurrent therapy, the specific composition or formulation employed, the particular cosmetically-acceptable topical carrier utilized, and like factors.
The compositions of this invention comprise polymerized wheat proteins of high molecular weight. These polymerized wheat proteins can be prepared by a process comprising the following steps 1) solubilizing in an aqueous phase a material which is rich in wheat proteins;
2) hydrolyzing by enzymatic reaction in a controlled and limited manner the solution of 1) wherein the level of enzymatic hydrolysis is selected such that monomeric proteins with a molar mass between 20,000 Da and 300,000 Da are obtained;
3) separating the soluble phases from the insoluble phases;
4) polymerizing the proteins by adding a suitable polymerizing agent.
The source of wheat proteins used in the first step can be any material derived from wheat that is sufficiently rich in wheat proteins. Suitable materials are, for example, wheat flour, wheat extracts, wheat gluten and the like.
The process preferably is conducted under following circumstances. The starting wheat protein rich material is solubilized at a concentration of 50 g/1 to 500 g/1.
Subsequently, the hydrolysis is carned out preferably in acid pH, preferably at a pH
level in the range between 4 and 7 and at a temperature between 40°C
and 80°C.
The enzymes that can be used in the hydrolysis step are proteases of the following type:
endoproteases, exoproteases, exopeptidases, proteasepeptidases, aminomeptidases or carbopeptidases, or a mixture of these enzymes. After completion of the reaction the enzymes are inactivated, for example by increasing the temperature of the reaction mixture to a temperature between 50°C and 80°C. The level of hydrolysis is selected such that the percentage of hydrolysed wheat protein in fractions F2 and F3 is between about 70 : 60 to about 50 : 40 and in particular is about 50 : 50 (+l- 5%), with no or almost no hydrolysed protein in fraction F1 (preferably less than about 5%), wherein Fl, F2 and F3 are as defined hereinafter.
The polymerizing agent preferably is a multifunctional polymerizing agent selected from the group of polymerization initiators comprising polychlorides of acids, acid polyanhydrides, polyisocyanates, polythioisocyanates. The polymerization step is preferably carried out with a level of polymerization agent between 10 g/1 and 100 g/1, selected so as to obtain a level of polymerized proteins that is higher than 30%.
Preferably about one equivalent of the polymerizing agent is used.
The separation of the polymerized wheat proteins can be carried out by filtration, decantation, centrifugation and concentration.
Particular polymerized wheat proteins as well as processes for their manufacture have been described in WO-03/040216, which is incorporated herein by reference.
The polymerized wheat proteins are characterized in that they contain - an amount of dry material, when obtained by heating the isolated polymerized protein at about 105°C until a constant weight is reached, of about 5 g/1 to about 500 g/1, preferably of about 50 g/1 to about 250 g/1;
- a pH, measured potentiometrically at room temperature, of about 2 to about 10, preferably of about 4 to about 10, more preferably of about 7 to about 8;
- a level of proteins, when measured with the Biuret method at 540 nm, of about 40 g/1 to about 400 g/l, preferably of about 40 g/1 to about 200 g/1;
- the size distribution of the proteins is defined by their chromatographic profile; the molar mass of the different molecules is determined by F.P.L.C (Fast Protein Liquid Chromotography) chromatography; by using a standard filtration column and calibrated with known markers of molar mass such as cytochrorne C, 12500 Da, alcohol deshydrogenase, 15000 Da, carboxylic anhydrase, 29000 Da, bovine albumine, 66000 Da, apoferritine, 443000 Da, thyroglobuline, 669000 Da; the detection of the eluted components is carried out by ultra-violet at 280 nm; a specific percentage of the proteins contained in each fraction, fraction Fl =
molar mass over to 500,000 Da, fraction F2 = molar mass between 150,000 and 500,000 Da and fraction F3 = molar mass inferior to 150,000 Da, preferably this percentage is about 30% to about 60% in fraction F1, in particular from about 40% to about 50%. The percentage of proteins in fraction F1 is from about 15% to about 35%, in particular from about 20% to about 25%. The percentage of proteins in fraction is from about 15% to about 45%, in particular from about 20% to about 40%, of particular interest are polymerized wheat proteins wherein the percentage of proteins in fraction Fl is about 45% (+/- 5%), in fraction F2 is about 30% (+/-5%) and in fraction F3 is about 25% (+/- 5%).
_7_ A particularly preferred polymerized wheat protein is available under the trade name 'Polymere de Ble' from the company Silab (France).
Figure 1 represents a chromotographical profile of the polymerized wheat protein 'Polymere de Ble'.
The compositions of the present invention contain an ethanolamine of formula (I) as defined above. As used herein C3_6 cycloalkyl refers to a cyclic cycloalkyl radical having from 3 to 6 carbon atoms and that preferably is saturated such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Cl_~ alkyl refers to straight and branch chained hydrocarbon radicals which preferably are saturated and have from 1 to 6 carbon atoms such as, for example, methyl, ethyl, n.propyl, iso-propyl, n.butyl, iso-butyl, t.butyl, n.
pentyl, iso-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-rnethylpentyl, 2,2-dimethylbutyl and the like. C1_4 alkyl refers to the same group of radicals having 1 to 4 carbon atoms.
A particularly preferred ethanolamine of formula (I) is I~MAE (deanol).
The ethanolamines of formula (I) can be prepared according to art-known procedures, e.g. by alkylating ethanolamine.
The ethanolamines of formula (I) can be used in their basic form or can be used as appropriate topically acceptable salts, the latter referring to acid-addition salt forms that are biologically acceptable for the skin and/or mucous membranes. Biologically acceptable in particular refers to lack of toxicity and of adverse effects such as irritation, allergic reactions and the like.
Suitable topically acceptable salts are those that are obtained by treating the base form of the ethanolamine of formula (I) with an appropriate acid. Suitable acids for use in the preparation of the ethanolamine salts according to the invention include any inorganic or, which is preferred, organic acid known to be useful in skin care compositions. These include acids such as, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; boric, sulfuric, nitric, _$_ phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic (or glycolic), lactic, pyruvic, oxalic, malonic, succinic, malefic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, ascorbic and the like acids.
In a preferred embodiment, at least one of the acids is an alpha hydroxy acid, such as taught for example in U.S. Patent No. 5,856,357, the disclosure of which is hereby incorporated by reference. Particularly preferred is a mixture of at least two of glycolic acid, malic acid and citric acids. In a most preferred embodiment, the acid is a combination of glycolic acid and either malic or citric acid. In situations where pH
stability is a particular concern, e.g., long term storage, a particularly preferred embodiment is when the acid is a mixture of citric and glycolic acid.
Preferably, the ratio of malic or citric acid to glycolic acid ranges from about 1:1 to about 1:5, more preferably, from about 1:1 to about 1:3.
Another compound, which is advantageously present in the compositions or formulations of this invention is tyrosine. Tyrosine may be present in the compositions or formulations of this invention in the amount of from about 0.01 to about 5%, more preferably from about 0.04 to about 3%v by weight and most preferably about 0.5% by weight, based on the total composition or formulation.
In general, the compositions of the present invention are prepared by mixing at least one polymerized wheat protein with at least one ethanolamine of formula (I) or a salt form thereof, and if desired by adding further ingredients. The polymerized wheat proteins preferably are formulated in an aqueous medium, optionally in the presence of suitable preservatives. The compositions of the present invention therefore are mostly of aqueous nature. They may be prepared by adding the aqueous formulations of polymerized wheat proteins to the ethanolamine of formula (I), or its salt form, or vice versa.
In the compositions of the present invention the w/w ratio of the ethanolamine (I) to the polymerized wheat proteins may vary but in particular is in the range of about 50 : 1 to about 1 : 1, in particular of about 20 : 1 to about 2 : 1, preferably from about 15 : 1 to about 5 : 1, more preferably the w/w ratio is about ~ : 1 to 7 : 1 (ethanolamine : wheat proteins). In these ratios, the quantity of ethanolanune is that of ethanolamine free base, meaning that if salts are used the ratios need to be recalculated accordingly.
Furthermore, the quantity of polymerized wheat protein referred to in this paragraph is that of dry material.
This invention further relates to topical formulations containing a composition as defined herein. Topical formulations comprise dermatological formulations (or topical pharmaceutical formulations), and cosmetic formulations. Said topical formulations may further contain other ingredients or additives used in dermatological or in cosmetic formulations, including other active ingredients. Examples of further ingredients or additives are surfactants, emulsifiers, consistency factors, conditioners, emollients, skin caring ingredients, moisturizers, thickeners, lubricants, fillers, binding agents, anti-oxidants, preservatives, active ingredients, in particular dermatologically active ingredients, fragrances and the like. Active ingredients as mentioned herein comprise, for example, anti-inflammatories, anti-bacterials, anti-fungals and the like agents. Of particular interest are any active ingredients suited for topical applications.
The topical formulations according to the invention can further include one or more of a variety of optional ingredients, such as coloring agents, opacifying agents and the like.
The ethanolamine and more specifically dimehylethanolamine may be used in the formulations for topical application at concentrations from about 0.01% to about 10%, preferably from about 0.1% to about 5%, more preferably from about 0.5% to about 5%.
The total amount of polymerized wheat proteins should be used in the formulations for topical application at concentrations which may vary between about 0.01 % to about 2%, preferably from about 0.05% to about 1%, more preferably from about 0.1%
to about 0.5%. As used in this paragraph, the percentages of polymerized wheat proteins refer to dry material.
The formulations according to the present invention can be prepared by adding the appropriate ingredients to a composition of the invention, or vice versa by adding the composition to an appropriate cosmetic or dermatological formulation base. It is also possible to mix all the ingredients individually, i.e. without making a separate composition as defined herein.
The topical formulations according to the invention may be in the form of a solution, a hydrophilic lotion, an ointment, a cream or a gel. The formulations may also be, for example, in the form of oil-in-water, water-in-oil or multiple emulsions, foaming products or in liposome form.
Of particular interest are formulations based on oil-in-water emulsions. In the latter instance an oil phase, containing the oil-soluble components, is made separately which is added to any of the aqueous phases containing suitable emulsifiers.
Preferably the first aqueous phase is made containing one or more suitable emulsifiers. The oil phase is made and added to the first phase while building an emulsion. Subsequently the second aqueous phase is added. In the instance where the first or oil phase contains solid or semi-solid components, it is recommendable to heat the phase or phases and to conduct the emulsifying process at elevated temperature.
The topical formulations according to the invention can further include one or more of a variety of additional ingredients commonly found in skin care compositions, such as for example, emollients, skin conditioning agents, emulsifying agents, humectants, preservatives, antioxidants, active ingredients, perfumes, chelating agents, dyes, opacifying agents, etc., provided that they are physically and chemically compatible with the other components of the composition. Notably useful is the incorporation of vitamin A and vitamin A derivatives, including but not restricted to retinol, retinyl palmitate, retinoic acid, retinal, and retinyl propionate.
Examples of other active agents which may be incorporated comprise anti-microbials, e.g. anti-bacterials and antifungals, anti-inflammatory agents, anti-irritating compounds, anti-itching agents, moisturising agents, skin caring ingredients, plant extracts, vitamins, and the like. Also included are sunscreen actives, which may be inorganic or organic in nature.
Examples of suitable preservatives for use in the compositions or formulations of the invention include the Cl-C4 alkyl parabens and phenoxyethanol. Generally, the preservative is present in an amount ranging from about 0.5 to about 2.0, preferably about 1.0 to about 1.5, weight percent based on the total composition. In a preferred embodiment, the preservative is a mixture of from about 0.2 to about 0.5 weight percent methylparaben, from about 0.2 to about 5.0 weight percent propylparaben and from about 0.05 to about 0.10 weight percent butylparaben.
Preferably, antioxidants should be present in the compositions or formulations according to the invention. Suitable antioxidants include butylated hydroxy toluene (BHT), ascorbyl palmitate, butylated hydroanisole (BHA), phenyl-a-naphthylamine, hydroquinone, propyl gallate, nordihydroquiaretic acid, vitamin E or derivatives of vitamin E, vitamin C and derivatives thereof, calcium pantothenic, green tea extracts and mixed polyphenols, and mixtures thereof of the above. When utilized the antioxidant can be present in an amount ranging from about 0.02 to about 0.5%
by weight, more preferably from about 0.002 to about 0.1% by weight of the total composition.
Emollients which can be included in the compositions or formulations of the invention function by their ability to remain on the skin surface or in the stratum corneum to act as lubricants, to reduce flaking, and to improve the skin appearance. Typical emollients include fatty esters, fatty alcohols, mineral oil, polyether siloxane copolymers and the like. Examples of suitable emollients include, but are riot limited to, polypropylene glycol ("PPG")-15 stearyl ether, PPG-10 cetyl ether, steareth-10, oleth-~, PPG-4 lauryl ether, vitamin E acetate, PEG-7 glyceryl cocoate, lanolin, cetyl alcohol, octyl hydroxystearate, dimethicone, and combinations thereof. Cetyl alcohol, octyl hydroxystearate, dimethicone, and combinations thereof are preferred.
When utilized, the emollient can be present in an amount from about 0.01 to about 5, preferably from about 1 to about 4 percent by weight based on the total composition.
Polyhydric alcohols can be utilized as humectants in the compositions or formulations of the invention. The humectants aid in increasing the effectiveness of the emollient, reduce scaling, stimulate removal of built-up scale and improve skin feel.
Suitable polyhydric alcohols include, but are not limited to, glycerol (also known as glycerine), polyalkylene glycols, alkylene polyols and their derivatives, including butylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol and derivatives thereof, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-dibutylene glycol, 1,2,6,-hexanetriol, ethoxylated glycerol, propoxylated glycerol and mixtures thereof. Glycerine is preferred. When utilized, the humectant is present in an amount from about 0.1 to about 5, preferably from about 1 to about 3 percent by weight, based on the total weight of the composition.
All the topical formulations as described above can also be applied on the skin by means of wipes.
The compositions and topical formulations subject of the present invention are useful to combat or to treat the effects of skin aging. The effects of skin aging comprise those associated with the aging of the skin such as the appearance of fine lines, fine wrinkling, wrinkling, loss of skin firmness, skin tightening and suppleness.
The compositions and formulations of the present invention additionally act beneficially on the mechanical properties of the epidermis, stimulate the proliferation of dermal cells and in particular the proliferation of fibroblasts, stimulate of collagen synthesis, have a positive effect on cell metabolism and on extracellular matrix synthesis in dermal fibroblasts. They moreover have a firming and tightening effect, provide a more youthful and smooth aspect of the skin, and have a positive effect on its general appearance, in particular of facial skin.
Additionally, certain ethanolamine derivatives and in particular DMAE, are known to have skin-lifting and skin tightening effects and therefore improve the appearance of the skin.
The polymerized wheat protein and the ethanolamines of formula (n act synergistically in their skin-lifting capability and therefore the compositions and formulations of the invention possess improved lifting capability. Moreover, quite unexpectedly it has been found that when using the compositions and formulations of the invention, the skin-lifting and skin-tightening effects are observed immediately and although the effect is immediate, it remains for a long period of time.
More specifically the known effects of the ethanolamines and in particular of DMAE
are amplified by the presence of the polymerized wheat proteins.
Examples The following example is meant to illustrate the invention and not to limit it thereto.
Ingredients % w/w Aqua X4.90 Sclerotium gum 0.75 Arachidyl alcohol 1.00 Behenyl Alcohol Arachidyl glucoside Caprylyl glycol 0.50 Glycerine 2.00 Methylparaben 0.15 Polymerized wheat protein (dry material) 0.33 Sodium Methyl Paraben/
Sodium Propyl Paraben/ 0.023 Sodium Ethyl Paraben Dimethicone 2.00 Cyclopentansiloxane 2.00 Ammonium Acryloyldimethyltaurate /VP 1.00 Copolymer Citric acid O,g7 Glycolic acid 1.73 Dimethyl MEA 2.50 Perfume 0.25 Total 100.00 The ingredients are mixed in ingredient groups as listed above (each group being separated by a blanc in the above table). The polymerized wheat protein is used dissolved in a small quantity of water together with the Paraberi mixture.
Subsequently the groups are mixed together to the end group.
Particular polymerized wheat proteins as well as processes for their manufacture have been described in WO-03/040216, which is incorporated herein by reference.
The polymerized wheat proteins are characterized in that they contain - an amount of dry material, when obtained by heating the isolated polymerized protein at about 105°C until a constant weight is reached, of about 5 g/1 to about 500 g/1, preferably of about 50 g/1 to about 250 g/1;
- a pH, measured potentiometrically at room temperature, of about 2 to about 10, preferably of about 4 to about 10, more preferably of about 7 to about 8;
- a level of proteins, when measured with the Biuret method at 540 nm, of about 40 g/1 to about 400 g/l, preferably of about 40 g/1 to about 200 g/1;
- the size distribution of the proteins is defined by their chromatographic profile; the molar mass of the different molecules is determined by F.P.L.C (Fast Protein Liquid Chromotography) chromatography; by using a standard filtration column and calibrated with known markers of molar mass such as cytochrorne C, 12500 Da, alcohol deshydrogenase, 15000 Da, carboxylic anhydrase, 29000 Da, bovine albumine, 66000 Da, apoferritine, 443000 Da, thyroglobuline, 669000 Da; the detection of the eluted components is carried out by ultra-violet at 280 nm; a specific percentage of the proteins contained in each fraction, fraction Fl =
molar mass over to 500,000 Da, fraction F2 = molar mass between 150,000 and 500,000 Da and fraction F3 = molar mass inferior to 150,000 Da, preferably this percentage is about 30% to about 60% in fraction F1, in particular from about 40% to about 50%. The percentage of proteins in fraction F1 is from about 15% to about 35%, in particular from about 20% to about 25%. The percentage of proteins in fraction is from about 15% to about 45%, in particular from about 20% to about 40%, of particular interest are polymerized wheat proteins wherein the percentage of proteins in fraction Fl is about 45% (+/- 5%), in fraction F2 is about 30% (+/-5%) and in fraction F3 is about 25% (+/- 5%).
_7_ A particularly preferred polymerized wheat protein is available under the trade name 'Polymere de Ble' from the company Silab (France).
Figure 1 represents a chromotographical profile of the polymerized wheat protein 'Polymere de Ble'.
The compositions of the present invention contain an ethanolamine of formula (I) as defined above. As used herein C3_6 cycloalkyl refers to a cyclic cycloalkyl radical having from 3 to 6 carbon atoms and that preferably is saturated such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Cl_~ alkyl refers to straight and branch chained hydrocarbon radicals which preferably are saturated and have from 1 to 6 carbon atoms such as, for example, methyl, ethyl, n.propyl, iso-propyl, n.butyl, iso-butyl, t.butyl, n.
pentyl, iso-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-rnethylpentyl, 2,2-dimethylbutyl and the like. C1_4 alkyl refers to the same group of radicals having 1 to 4 carbon atoms.
A particularly preferred ethanolamine of formula (I) is I~MAE (deanol).
The ethanolamines of formula (I) can be prepared according to art-known procedures, e.g. by alkylating ethanolamine.
The ethanolamines of formula (I) can be used in their basic form or can be used as appropriate topically acceptable salts, the latter referring to acid-addition salt forms that are biologically acceptable for the skin and/or mucous membranes. Biologically acceptable in particular refers to lack of toxicity and of adverse effects such as irritation, allergic reactions and the like.
Suitable topically acceptable salts are those that are obtained by treating the base form of the ethanolamine of formula (I) with an appropriate acid. Suitable acids for use in the preparation of the ethanolamine salts according to the invention include any inorganic or, which is preferred, organic acid known to be useful in skin care compositions. These include acids such as, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; boric, sulfuric, nitric, _$_ phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic (or glycolic), lactic, pyruvic, oxalic, malonic, succinic, malefic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, ascorbic and the like acids.
In a preferred embodiment, at least one of the acids is an alpha hydroxy acid, such as taught for example in U.S. Patent No. 5,856,357, the disclosure of which is hereby incorporated by reference. Particularly preferred is a mixture of at least two of glycolic acid, malic acid and citric acids. In a most preferred embodiment, the acid is a combination of glycolic acid and either malic or citric acid. In situations where pH
stability is a particular concern, e.g., long term storage, a particularly preferred embodiment is when the acid is a mixture of citric and glycolic acid.
Preferably, the ratio of malic or citric acid to glycolic acid ranges from about 1:1 to about 1:5, more preferably, from about 1:1 to about 1:3.
Another compound, which is advantageously present in the compositions or formulations of this invention is tyrosine. Tyrosine may be present in the compositions or formulations of this invention in the amount of from about 0.01 to about 5%, more preferably from about 0.04 to about 3%v by weight and most preferably about 0.5% by weight, based on the total composition or formulation.
In general, the compositions of the present invention are prepared by mixing at least one polymerized wheat protein with at least one ethanolamine of formula (I) or a salt form thereof, and if desired by adding further ingredients. The polymerized wheat proteins preferably are formulated in an aqueous medium, optionally in the presence of suitable preservatives. The compositions of the present invention therefore are mostly of aqueous nature. They may be prepared by adding the aqueous formulations of polymerized wheat proteins to the ethanolamine of formula (I), or its salt form, or vice versa.
In the compositions of the present invention the w/w ratio of the ethanolamine (I) to the polymerized wheat proteins may vary but in particular is in the range of about 50 : 1 to about 1 : 1, in particular of about 20 : 1 to about 2 : 1, preferably from about 15 : 1 to about 5 : 1, more preferably the w/w ratio is about ~ : 1 to 7 : 1 (ethanolamine : wheat proteins). In these ratios, the quantity of ethanolanune is that of ethanolamine free base, meaning that if salts are used the ratios need to be recalculated accordingly.
Furthermore, the quantity of polymerized wheat protein referred to in this paragraph is that of dry material.
This invention further relates to topical formulations containing a composition as defined herein. Topical formulations comprise dermatological formulations (or topical pharmaceutical formulations), and cosmetic formulations. Said topical formulations may further contain other ingredients or additives used in dermatological or in cosmetic formulations, including other active ingredients. Examples of further ingredients or additives are surfactants, emulsifiers, consistency factors, conditioners, emollients, skin caring ingredients, moisturizers, thickeners, lubricants, fillers, binding agents, anti-oxidants, preservatives, active ingredients, in particular dermatologically active ingredients, fragrances and the like. Active ingredients as mentioned herein comprise, for example, anti-inflammatories, anti-bacterials, anti-fungals and the like agents. Of particular interest are any active ingredients suited for topical applications.
The topical formulations according to the invention can further include one or more of a variety of optional ingredients, such as coloring agents, opacifying agents and the like.
The ethanolamine and more specifically dimehylethanolamine may be used in the formulations for topical application at concentrations from about 0.01% to about 10%, preferably from about 0.1% to about 5%, more preferably from about 0.5% to about 5%.
The total amount of polymerized wheat proteins should be used in the formulations for topical application at concentrations which may vary between about 0.01 % to about 2%, preferably from about 0.05% to about 1%, more preferably from about 0.1%
to about 0.5%. As used in this paragraph, the percentages of polymerized wheat proteins refer to dry material.
The formulations according to the present invention can be prepared by adding the appropriate ingredients to a composition of the invention, or vice versa by adding the composition to an appropriate cosmetic or dermatological formulation base. It is also possible to mix all the ingredients individually, i.e. without making a separate composition as defined herein.
The topical formulations according to the invention may be in the form of a solution, a hydrophilic lotion, an ointment, a cream or a gel. The formulations may also be, for example, in the form of oil-in-water, water-in-oil or multiple emulsions, foaming products or in liposome form.
Of particular interest are formulations based on oil-in-water emulsions. In the latter instance an oil phase, containing the oil-soluble components, is made separately which is added to any of the aqueous phases containing suitable emulsifiers.
Preferably the first aqueous phase is made containing one or more suitable emulsifiers. The oil phase is made and added to the first phase while building an emulsion. Subsequently the second aqueous phase is added. In the instance where the first or oil phase contains solid or semi-solid components, it is recommendable to heat the phase or phases and to conduct the emulsifying process at elevated temperature.
The topical formulations according to the invention can further include one or more of a variety of additional ingredients commonly found in skin care compositions, such as for example, emollients, skin conditioning agents, emulsifying agents, humectants, preservatives, antioxidants, active ingredients, perfumes, chelating agents, dyes, opacifying agents, etc., provided that they are physically and chemically compatible with the other components of the composition. Notably useful is the incorporation of vitamin A and vitamin A derivatives, including but not restricted to retinol, retinyl palmitate, retinoic acid, retinal, and retinyl propionate.
Examples of other active agents which may be incorporated comprise anti-microbials, e.g. anti-bacterials and antifungals, anti-inflammatory agents, anti-irritating compounds, anti-itching agents, moisturising agents, skin caring ingredients, plant extracts, vitamins, and the like. Also included are sunscreen actives, which may be inorganic or organic in nature.
Examples of suitable preservatives for use in the compositions or formulations of the invention include the Cl-C4 alkyl parabens and phenoxyethanol. Generally, the preservative is present in an amount ranging from about 0.5 to about 2.0, preferably about 1.0 to about 1.5, weight percent based on the total composition. In a preferred embodiment, the preservative is a mixture of from about 0.2 to about 0.5 weight percent methylparaben, from about 0.2 to about 5.0 weight percent propylparaben and from about 0.05 to about 0.10 weight percent butylparaben.
Preferably, antioxidants should be present in the compositions or formulations according to the invention. Suitable antioxidants include butylated hydroxy toluene (BHT), ascorbyl palmitate, butylated hydroanisole (BHA), phenyl-a-naphthylamine, hydroquinone, propyl gallate, nordihydroquiaretic acid, vitamin E or derivatives of vitamin E, vitamin C and derivatives thereof, calcium pantothenic, green tea extracts and mixed polyphenols, and mixtures thereof of the above. When utilized the antioxidant can be present in an amount ranging from about 0.02 to about 0.5%
by weight, more preferably from about 0.002 to about 0.1% by weight of the total composition.
Emollients which can be included in the compositions or formulations of the invention function by their ability to remain on the skin surface or in the stratum corneum to act as lubricants, to reduce flaking, and to improve the skin appearance. Typical emollients include fatty esters, fatty alcohols, mineral oil, polyether siloxane copolymers and the like. Examples of suitable emollients include, but are riot limited to, polypropylene glycol ("PPG")-15 stearyl ether, PPG-10 cetyl ether, steareth-10, oleth-~, PPG-4 lauryl ether, vitamin E acetate, PEG-7 glyceryl cocoate, lanolin, cetyl alcohol, octyl hydroxystearate, dimethicone, and combinations thereof. Cetyl alcohol, octyl hydroxystearate, dimethicone, and combinations thereof are preferred.
When utilized, the emollient can be present in an amount from about 0.01 to about 5, preferably from about 1 to about 4 percent by weight based on the total composition.
Polyhydric alcohols can be utilized as humectants in the compositions or formulations of the invention. The humectants aid in increasing the effectiveness of the emollient, reduce scaling, stimulate removal of built-up scale and improve skin feel.
Suitable polyhydric alcohols include, but are not limited to, glycerol (also known as glycerine), polyalkylene glycols, alkylene polyols and their derivatives, including butylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol and derivatives thereof, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-dibutylene glycol, 1,2,6,-hexanetriol, ethoxylated glycerol, propoxylated glycerol and mixtures thereof. Glycerine is preferred. When utilized, the humectant is present in an amount from about 0.1 to about 5, preferably from about 1 to about 3 percent by weight, based on the total weight of the composition.
All the topical formulations as described above can also be applied on the skin by means of wipes.
The compositions and topical formulations subject of the present invention are useful to combat or to treat the effects of skin aging. The effects of skin aging comprise those associated with the aging of the skin such as the appearance of fine lines, fine wrinkling, wrinkling, loss of skin firmness, skin tightening and suppleness.
The compositions and formulations of the present invention additionally act beneficially on the mechanical properties of the epidermis, stimulate the proliferation of dermal cells and in particular the proliferation of fibroblasts, stimulate of collagen synthesis, have a positive effect on cell metabolism and on extracellular matrix synthesis in dermal fibroblasts. They moreover have a firming and tightening effect, provide a more youthful and smooth aspect of the skin, and have a positive effect on its general appearance, in particular of facial skin.
Additionally, certain ethanolamine derivatives and in particular DMAE, are known to have skin-lifting and skin tightening effects and therefore improve the appearance of the skin.
The polymerized wheat protein and the ethanolamines of formula (n act synergistically in their skin-lifting capability and therefore the compositions and formulations of the invention possess improved lifting capability. Moreover, quite unexpectedly it has been found that when using the compositions and formulations of the invention, the skin-lifting and skin-tightening effects are observed immediately and although the effect is immediate, it remains for a long period of time.
More specifically the known effects of the ethanolamines and in particular of DMAE
are amplified by the presence of the polymerized wheat proteins.
Examples The following example is meant to illustrate the invention and not to limit it thereto.
Ingredients % w/w Aqua X4.90 Sclerotium gum 0.75 Arachidyl alcohol 1.00 Behenyl Alcohol Arachidyl glucoside Caprylyl glycol 0.50 Glycerine 2.00 Methylparaben 0.15 Polymerized wheat protein (dry material) 0.33 Sodium Methyl Paraben/
Sodium Propyl Paraben/ 0.023 Sodium Ethyl Paraben Dimethicone 2.00 Cyclopentansiloxane 2.00 Ammonium Acryloyldimethyltaurate /VP 1.00 Copolymer Citric acid O,g7 Glycolic acid 1.73 Dimethyl MEA 2.50 Perfume 0.25 Total 100.00 The ingredients are mixed in ingredient groups as listed above (each group being separated by a blanc in the above table). The polymerized wheat protein is used dissolved in a small quantity of water together with the Paraberi mixture.
Subsequently the groups are mixed together to the end group.
Claims (9)
1. A composition comprising at least one ethanolamine derivative of formula (I), or a topically acceptable salt thereof:
wherein in formula (I) R1 and R2 independently represent hydrogen, C3-6 cycloalkyl or C1-6 alkyl, optionally substituted with hydroxy, methoxy, oxo or formy, and at least a polymerized wheat protein.
wherein in formula (I) R1 and R2 independently represent hydrogen, C3-6 cycloalkyl or C1-6 alkyl, optionally substituted with hydroxy, methoxy, oxo or formy, and at least a polymerized wheat protein.
2. A composition according to claim 1 wherein R1 and R2 independently represent C1-4 alkyl.
3. A composition according to claim 1 or 2 wherein the ethanolamine of formula (I) is dimethylaminoethanol (DMAE).
4. A composition according to any of claims 1 - 3 wherein the ethanolamine of formula (I) is present as a glycolate or citrate or mixed glycolate/citrate salt form.
5. A composition according to claims 1 to 4 wherein the polymerized wheat protein is obtainable by a process comprising the following steps:
(a) solubilizing in an aqueous phase a material which is rich in wheat proteins;
(b) hydrolyzing by enzymatic reaction in a controlled and limited manner the solution of 1) wherein the level of enzymatic hydrolysis is selected such that monomeric proteins with a molar mass between 20,000 Da and 300,000 Da are obtained;
(c) separating the soluble phases from the insoluble phases;
(d) polymerizing the proteins by adding a suitable polymerizing agent.
(a) solubilizing in an aqueous phase a material which is rich in wheat proteins;
(b) hydrolyzing by enzymatic reaction in a controlled and limited manner the solution of 1) wherein the level of enzymatic hydrolysis is selected such that monomeric proteins with a molar mass between 20,000 Da and 300,000 Da are obtained;
(c) separating the soluble phases from the insoluble phases;
(d) polymerizing the proteins by adding a suitable polymerizing agent.
6. A composition according to claim 5 wherein the polymerized wheat protein has a molecular distribution such that the fraction having a molar mass over 500,000 Da is present in an amount which is in the range of about 30% to about 60% (weight %).
7. A topical formulation comprising a composition as claimed in claims 1-6 and further ingredients.
8. Use of a composition as claimed in claims 1-6 for manufacturing a topical or in particular a cosmetic formulation.
9. Use of a composition as claimed in claims 1-6 or of a formulation as claimed in claim 7 for combating or treating the effects associated with the aging of skin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03290026.8 | 2003-01-06 | ||
EP03290026 | 2003-01-06 | ||
PCT/EP2004/000141 WO2004060339A1 (en) | 2003-01-06 | 2004-01-06 | Compositions of polymerized wheat proteins and ethanolamine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2512249A1 true CA2512249A1 (en) | 2004-07-22 |
Family
ID=32695660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002512249A Abandoned CA2512249A1 (en) | 2003-01-06 | 2004-01-06 | Compositions of polymerized wheat proteins and ethanolamine derivatives |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1581179A1 (en) |
BR (1) | BRPI0406630A (en) |
CA (1) | CA2512249A1 (en) |
WO (1) | WO2004060339A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1875895A1 (en) | 2006-07-07 | 2008-01-09 | Johnson & Johnson Consumer France SAS | Electrolyte containing compositions having enhanced viscosity |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554647A (en) * | 1989-10-12 | 1996-09-10 | Perricone; Nicholas V. | Method and compositions for treatment and/or prevention of skin damage and aging |
FR2775185B1 (en) * | 1998-02-23 | 2001-09-07 | Fabre Pierre Dermo Cosmetique | COSMETIC COMPOSITION COMPRISING TRACE ELEMENTS FROM MINERAL AND CHELATED WATERS BY VEGETABLE PROTEIN HYDROLYSATES |
FR2801504B1 (en) * | 1999-11-26 | 2002-02-15 | Lvmh Rech | EXTRACT OF AJUGA TURKESTANICA AND ITS COSMETIC APPLICATIONS |
US20030095991A1 (en) * | 2000-10-02 | 2003-05-22 | Curtis Cole | Treatment for skin |
-
2004
- 2004-01-06 WO PCT/EP2004/000141 patent/WO2004060339A1/en active Application Filing
- 2004-01-06 BR BR0406630-8A patent/BRPI0406630A/en not_active IP Right Cessation
- 2004-01-06 CA CA002512249A patent/CA2512249A1/en not_active Abandoned
- 2004-01-06 EP EP04700259A patent/EP1581179A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2004060339A1 (en) | 2004-07-22 |
BRPI0406630A (en) | 2005-12-06 |
EP1581179A1 (en) | 2005-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1216696B1 (en) | Method for reducing the appearance of dark circles under the eyes | |
JP3112436B2 (en) | In particular, the use of honey as a keratolytic agent to improve the brightness of the skin facial and treat wrinkles | |
US20050053563A1 (en) | Stable compositions containing ethanolamine derivatives and glucosides | |
JPWO2007013662A1 (en) | Anti-wrinkle / improving agent | |
CA2457039A1 (en) | Compositions comprising an ethanolamine derivative and organic metal salts | |
JP3023088B2 (en) | Use of oxamate derivatives as depigmenting agents | |
EP2694025B1 (en) | Use of ethyl gingerone or derivatives thereof for reducing or delaying the signs of skin ageing | |
US20030095991A1 (en) | Treatment for skin | |
JP3280903B2 (en) | External preparation for skin | |
AU2004290893A1 (en) | Compositions comprising soy products and dioic acids | |
JP2003012486A (en) | Skin care preparation | |
EP1551364B1 (en) | Thickener compositions comprising sclerotium gum and a copolymer | |
JP3278138B2 (en) | External preparation for skin | |
JPH10212225A (en) | Wrinkle preventive | |
CA2512249A1 (en) | Compositions of polymerized wheat proteins and ethanolamine derivatives | |
CN109195578A (en) | Purposes of the phosphorothioate derivative as Solu-Eze | |
JP3382146B2 (en) | External preparation for skin | |
JP3023543B2 (en) | Tyrosinase activity inhibitor and cosmetic | |
JP2002029957A (en) | Cosmetic | |
JP2002284666A (en) | Cosmetics | |
JP2003171226A (en) | Skin care preparation | |
JP2000063255A (en) | Preparation for external use for skin | |
JP2024132905A (en) | QSOX1 gene expression enhancer | |
JP2000256163A (en) | Skin lotion | |
WO2004096167A1 (en) | Composition containing ethanolamine derivatives and citric acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |